Daily Medication Pearl: Belzutifan (Welireg)

Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors.

Medication Pearl of the Day: Belzutifan (Welireg)

Indication: Belzutifanis a hypoxia-inducible factor inhibitor indicated for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.

Insight:

  • Dosing: The recommended dosage of belzutifanis 120 mg administered orally once daily with or without food.
  • Dosage forms:Tablets 40 mg.
  • Adverse events (AEs): The most common (≥ 25%) AEs, including laboratory abnormalities, were decreased hemoglobin, anemia, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea.
  • Mechanism of action: Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). HIF-2α is a transcription factor that plays a role in oxygen sensing by regulating genes that promote adaptation to hypoxia.
  • Manufacturer: Merck

Sources: